In the BioHarmony Drug Report Database

"Preview" Icon

Emapalumab-lzsg

Gamifant (emapalumab) is an antibody pharmaceutical. Emapalumab was first approved as Gamifant on 2018-11-20. It is used to treat hemophagocytic lymphohistiocytosis in the USA. The pharmaceutical is active against interferon gamma.

 

Trade Name

 

Gamifant
 

Common Name

 

emapalumab
 

ChEMBL ID

 

CHEMBL3989977
 

Indication

 

hemophagocytic lymphohistiocytosis
 

Drug Class

 

Monoclonal antibodies: fully human, immunomodulating

Image (chem structure or protein)

Emapalumab-lzsg structure rendering